Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Douglas Ingram
Biotech
Sarepta's DMD gene therapy fails phase 2 motor function test
Functional motor ability scores in the SRP-9001 arm were statistically no better than in the placebo group, almost halving Sarepta’s stock price.
Nick Paul Taylor
Jan 8, 2021 8:10am
Sarepta taps Codiak's exosome tech in $72.5M neuromuscular deal
Jun 23, 2020 10:00am
Sarepta CEO dispels FDA 'bias' theory
Nov 8, 2019 8:12am
Sarepta sees muscle gains with DMD gene therapy
Oct 4, 2018 11:00am
Sarepta boosts gene therapy with $30M Lacerta deal
Aug 9, 2018 10:39am
Sarepta adds to gene therapy pipeline via Myonexus pact
May 4, 2018 9:08am
